Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...